N-acetyl cysteine reverts the proinflammatory state induced by cigarette smoke extract in lung Calu-3 cells by Valdivieso, Ángel Gabriel et al.
Contents lists available at ScienceDirect
Redox Biology
journal homepage: www.elsevier.com/locate/redox
Research paper
N-acetyl cysteine reverts the proinﬂammatory state induced by cigarette
smoke extract in lung Calu-3 cells
Ángel G. Valdiviesoa,⁎, Andrea V. Dugourb, Verónica Sotomayora, Mariángeles Clauzurea,
Juan M. Figueroab, Tomás A. Santa-Colomaa,⁎
a Institute for Biomedical Research (BIOMED, UCA-CONICET), Laboratory of Cellular and Molecular Biology, School of Medical Sciences, Pontiﬁcal Catholic University of
Argentina (UCA) and The National Scientiﬁc and Technical Research Council of Argentina (CONICET), Alicia Moreau de Justo 1600, Buenos Aires C1107AFF, Argentina
b Fundación Pablo Cassará, Buenos Aires, Argentina
A R T I C L E I N F O
Keywords:
Cigarette smoke extract
Mitochondria
CFTR
ROS
COPD
Cystic ﬁbrosis
A B S T R A C T
Chronic obstructive pulmonary disease (COPD) and cystic ﬁbrosis (CF) are lethal pulmonary diseases. Cigarette
consumption is the main cause for development of COPD, while CF is produced by mutations in the CFTR gene.
Although these diseases have a diﬀerent etiology, both share a CFTR activity impairment and proinﬂammatory
state even under sterile conditions. The aim of this work was to study the extent of the protective eﬀect of the
antioxidant N-acetylcysteine (NAC) over the proinﬂammatory state (IL-6 and IL-8), oxidative stress (reactive
oxygen species, ROS), and CFTR levels, caused by Cigarette Smoke Extract (CSE) in Calu-3 airway epithelial
cells. CSE treatment (100 µg/ml during 24 h) decreased CFTR mRNA expression and activity, and increased the
release of IL-6 and IL-8. The eﬀect on these cytokines was inhibited by N-acetyl cysteine (NAC, 5mM) or the NF-
kB inhibitor, IKK-2 (10 µM). CSE treatment also increased cellular and mitochondrial ROS levels. The cellular
ROS levels were normalized to control values by NAC treatment, although signiﬁcant eﬀects on mitochondrial
ROS levels were observed only at short times (5´) and eﬀects on CFTR levels were not observed. In addition, CSE
reduced the mitochondrial NADH-cytochrome c oxidoreductase (mCx I-III) activity, an eﬀect that was not re-
verted by NAC. The reduced CFTR expression and the mitochondrial damage induced by CSE could not be
normalized by NAC treatment, evidencing the need for a more speciﬁc reagent. In conclusion, CSE causes a
sterile proinﬂammatory state and mitochondrial damage in Calu-3 cells that was partially recovered by NAC
treatment.
1. Introduction
Smoking, both active and passive, is the mayor non-infectious cause
of respiratory disease and constitutes a risk factor for respiratory in-
fections. Chronic obstructive pulmonary disease (COPD) is caused by
environmental and genetic factors, and is characterized by chronic
cough, respiratory secretions and progressive dyspnea and ﬁbrosis,
produced by chronic exposure of susceptible individuals to cigarette
smoke (CS) [1]. The risk of disease increases proportionally to the
amount of cigarettes smoked per day, although other factors, such as
high exposure to dust, chemicals, and genetic factors (mutations in the
α1-antitrypsin gene), could promote COPD [2].
Even though they are of diﬀerent etiology, COPD shares similar
respiratory symptoms with Cystic Fibrosis (CF) [1]. CF is an autosomal
recessive disease [3] caused by mutations in the cystic ﬁbrosis trans-
membrane conductance regulator (CFTR) gene, which encodes a
chloride channel regulated by adenosine triphosphate (ATP) and 3´,5´-
cyclic adenosine monophosphate (cAMP) [4,5]. Both, COPD and CF, are
characterized by airﬂow limitation, strong inﬂammatory response, re-
current infections, and progressive loss of lung function [1]. In the last
years, several reports show that COPD is also associated with altera-
tions in the CFTR channel function [1,6–12]. Studies in CF suggest that
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the impairment of the CFTR is associated with an alteration of the
mitochondrial function, in particular the mitochondrial complex I
(mCx-I) activity and reactive oxygen species (ROS) production [13–18].
The extent to which CF and COPD share similar pathological mechan-
isms could be of interest to identify new therapeutic targets for both
diseases.
A common adverse characteristic of COPD and CF is a strong in-
ﬂammatory response, initiated with the increased secretion of proin-
ﬂammatory cytokines and ROS levels [1]. In the treatment of re-
spiratory diseases, the antioxidant N-acetylcysteine (NAC) has emerged
as a mucolytic, antioxidant and anti-inﬂammatory drug [19,20]. NAC
antioxidant eﬀects occurs directly, through its free sulfhydryl group
that serves as a source of reducing equivalents, and indirectly, through
the replenishment of intracellular GSH levels [21]. In fact, NAC acts as a
cysteine precursor for the synthesis of glutathione (GSH), increasing the
antioxidant protection of the cells [22].
The aim of this work was to study the extent of the protective eﬀect
of the antioxidant N-acetylcysteine (NAC) over the proinﬂammatory
state and oxidative stress caused by CSE [7,19,23]. For this purpose we
used cultured Calu-3 airway cells as a model system, measuring the
secretion of the cytokines IL-6 and IL-8 as proinﬂammatory markers
[23]. Calu-3 cells express high levels of CFTR [24] and constitute a
good in vitro model to study human respiratory function, inﬂammatory
responses and diseases [25]. In cells exposed to CSE, we observed an
increased IL-6 and IL-8 secretion induced through NF-κB activation,
together with a reduced CFTR expression and activity. The reduction in
the CFTR expression could not be reverted by NAC. However, the in-
creased secretion of these cytokines was blocked by NAC, suggesting
that ROS contributed to the NF-κB activation. We also demonstrated a
fast induction of the mitochondrial ROS levels (mtROS) and a later
mitochondrial NADH cytochrome c oxidoreductase (Complex I-III) ac-
tivity impairment that could not be improved with NAC treatment. The
NAC eﬀects over ROS and cytokine levels suggest that an antioxidant
treatment may help to reduce inﬂammation in COPD; it also evidences
the need for an antioxidant therapy directed to speciﬁcally reduce the
mitochondrial oxidative stress and damage to the oxidative phosphor-
ylation system (OXPHOS) induced by CSE, which was not reverted with
NAC treatment. On the other hand, the possible CFTR role in the
proinﬂammatory response is not clear yet.
2. Materials and methods
2.1. Chemicals
Dimethyl sulfoxide (DMSO, culture grade), valinomycin, dibutyryl-
cAMP, IBMX (3-isobutyl-1-methylxanthine), cytochrome c and (-)-iso-
proterenol hydrochloride were purchased from Sigma-Aldrich (St.
Louis, MO). Trypsin was purchased from Life Technologies (GIBCO
BRL, Rockville, MD) and SPQ (6-methoxy-N-[3-sulfopropyl]quinoli-
nium) from Invitrogen (Carlsbad, CA). MitoSOX and 2´,7´-dichloro-
ﬂuorescein diacetate (DCFH-DA) was from Molecular Probes (Eugene,
OR). The IKK-2 inhibitor SC-514 (CAS 354812–17-2) was from
Calbiochem (San Diego, CA). Cigarette smoke extract (CSE) (stock so-
lution 40mg/ml in DMSO) was from Murty Pharmaceuticals
(Lexington, KY). N-acetylcysteine (NAC) (0.5M stock solution in water
(pH = 7.4)) was purchased from PharmaZell (PharmaZell, Chennai und
Vizag, India). All other reagents were analytical grade. The stock so-
lutions of valinomycin, IBMX, and dibutyryl-cAMP were prepared at
1000× in culture-grade DMSO. Isoproterenol was dissolved in water at
1000× concentration.
2.2. Cell culture
Calu-3 cells (ATCC Cat# HTB55), epithelial airway cells known to
express wt-CFTR [24], were used in the experiments. Cells were cul-
tured in DMEM (Life Technologies, GIBCO BRL, Rockville, MD)
supplemented with 10% FBS (Life Technologies, GIBCO BRL, Rockville,
MD), 100 U/ml penicillin, 100 µg/ml streptomycin, and 0.25 µg/ml
amphotericin B (GIBCO BRL).
2.3. CSE exposure
Cells were incubated with CSE at the concentrations and times in-
dicated for each assay. For viability assays, 10–200 µg/ml CSE were
used for various times (5–72 h). For the rest of the experiments, cells
were exposed to 100 µg/ml CSE during 24 h since this concentration
and time did not negatively aﬀect viability. Control cells contained the
same ﬁnal amount of DMSO (0.25%) [26] as in CSE exposed cells.
2.4. Cell viability and proliferation assays
Calu-3 cells were grown in 96-well plates (10,000 cells/cm2 in
100 µl of DMEM-10% FBS medium). The cells were incubated with
diﬀerent concentrations of CSE (10, 50, 100 and 200 μg/ml), or the
vehicle (DMSO) at diﬀerent times (0, 5, 24, 48 and 72 h). We used a
commercial cigarette smoke extract (CSE) to assure the reproducibility
of the assays. Cell viability was evaluated by using the CellTiter 96®
AQueous One Solution Cell Proliferation Assay (Promega, Madison,
WI), according to manufacturer´s instructions. Brieﬂy, after washing
with PBS, pH 7.4, cells were treated with staining solution containing
the tetrazolium compound MTS [3-(4,5-dimethylthiazol-2-yl)−5-(3-
carboxymethoxyphenyl)−2-(4-sulfophenyl)−2H-tetrazolium, inner
salt] and an electron coupling reagent (phenazine ethosulfate; PES).
Absorbance was recorded at 490 nm using a microplate reader (model
Benchmark, Bio-Rad, Hercules, CA).
2.5. Quantitative real-time RT-PCR (RT-qPCR)
To determine CFTR mRNA expression levels, RT-qPCRs were per-
formed and the ΔΔCt method was used for comparative quantiﬁcation,
as previously described [17,27]. Brieﬂy, total RNA (4 μg) from Calu-3
cells, treated with 100 µg/ml CSE or vehicle for 24 h, was used for re-
verse transcription by using M-MLV Reverse Transcriptase (Promega)
and Oligo-dT, according to the manufacturer's instructions (100 U of
RT/μg of RNA). PCR conditions were performed as previously described
[17,27]. qRT-PCR reactions were carried out in an Applied Biosystems
7500 Real-Time PCR equipment, and thermocycler conditions were:
denaturation at 94 °C (5min), and 40 cycles of 94 °C (30 s), 60 °C (30 s),
and 72 °C (30 s).
2.6. CFTR transport activity in Calu-3 cells
The ﬂuorescent probe SPQ was used to measure the CFTR chloride
transport activity, as we previously described [17,27,28], with some
modiﬁcations. Calu-3 cells were seeded at a density of 40,000 cells/cm2
in 2ml of medium and grown at conﬂuence in p6 wells plates con-
taining one rectangular coverslips (22× 8mm, from Hitachi) pre-
treated with a coating solution (10 µg/ml ﬁbronectin, 4.4 µg/ml col-
lagen, 1.5 µg/ml BSA in DMEM/F12). The cells were incubated with
100 μg/ml CSE or the vehicle for 24 h. Cells were loaded with SPQ by
hypotonic shock by using 5mM SPQ (dissolved 1:1 in serum-free
DMEM/F12:H2O distilled and sterile, washed three times with NaI
buﬀer (135mM NaI, 10mM Glucose, 1 mM CaSO4, 1mM MgSO4,
10mM HEPES, 2.4 mM K2HPO4, and 0.6mM KH2PO4, pH 7.4)) and
maintained in NaI at 37 °C for 30min. The measurement of the CFTR
activity was performed as previously described [28]. Data was plotted
as F/Fi −1 vs time (F: ﬂuorescence; Fi: initial ﬂuorescence measured
after the NaI buﬀer perfusion). The halide eﬄux slopes were estimated
by using the initial 6 points of time after the CFTR response to stimu-
lation started.
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2.7. Secretion of IL-8 and IL-6
Calu-3 cells were seeded (27,000 cells/cm2 in 100 µl of DMEM-10%
FBS medium) in 96 well-plates and grown to conﬂuence. The cells were
then incubated with 100 μg/ml CSE, 100 μg/ml CSE plus 10 μM IKK-2
inhibitor, 100 μg/ml CSE plus 5mM NAC or the vehicle for 24 h. IL-6
and IL-8 were measured from supernatants using the human IL-6 and
IL-8 ELISA set (BD OptEIA™ - Human IL-8 ELISA Set, and BD OptEIA™-
Human IL-6 ELISA Set, BD Biosciences, San Diego, CA). Measurements
were performed using a microplate reader according to manufacturer´s
instructions (model Benchmark, Bio-Rad).
2.8. Cellular reactive oxygen species (ROS)
Cellular ROS levels were measured using the ﬂuorescent probe
DCFH-DA in cells cultured in 96-well plates (Greiner Bio-One,
Germany; 655,090) as previously reported [13]. Brieﬂy, 27,000 cells/
cm2 were seeded and grown to conﬂuence in DMEM − 10% FBS
medium. Then, cells were incubated in Hank´s buﬀer containing 10 µM
of DCFH-DA and incubated at 37 °C in a 5% CO2/air incubator for
40min. Then, cells were washed ﬁve times with Hank´s buﬀer and
treated for 1 h with DMSO as vehicle, 100 μg/ml CSE or 100 μg/ml CSE
plus 5mM NAC. The ﬂuorescence was measured at diﬀerent times to
determine the maximal signal in a ﬂuorescence plate reader (NOVOstar
BMG LABTECH GmbH, Ortenberg, Germany) at 37 °C. Filters were
Ex=510 ± 10 nm, Em=540 ± 10 nm and readings were performed
by using 10 cycles (3 ﬂashes per well and cycle; excitation and mea-
surements were done from the bottom of the plate).
2.9. Confocal microscopy for cytoplasmic ROS measurement
To test the intracellular ﬂuorescence signal and discard background,
the DCF ﬂuorescence was observed in a Zeiss LSM 510 confocal mi-
croscope (Plan-Neoﬂuar 100×/1.3 Oil objective) (Carl Zeiss, Jena,
Germany). Brieﬂy, Calu-3 cells were seeded (27,000 cells/cm2) on
chambered coverglasses (4-chamber, Nunc, Cat. No. 155383, Lab-Tek,
Thermo Fisher Scientiﬁc, Rochester, NY) and cultured in DMEM-10%
FBS medium. Cells were incubated in Hank´s buﬀer containing 10 µM of
DCFH-DA and incubated at 37 °C in a 5% CO2/air incubator for 40min.
Then, cells were washed with 0.4ml of Hank´s buﬀer ﬁve times and
incubated with vehicle, 100 μg/ml CSE or 100 μg/ml CSE plus 5mM
NAC for 1 h. Cell images were acquired by using a LSM 510 Zeiss
confocal microscope with a laser line of 488 nm and a long-pass ﬁlter
LP505. The detector gain, oﬀset, laser potency and pinhole were
maintained for all conditions to compare the ﬂorescence intensity.
2.10. Confocal microscopy for mitochondrial ROS measurement
To measure mtROS, cells were cultured as above indicated for
DCFH-DA, changing the probe to MitoSOX (5 µM), and incubating at
37 °C in a 5% CO2/air incubator for 10min. Then, cells were washed
with Hank´s buﬀer four times (one minute each) and incubated in
100 µl of Hank's buﬀer. In vivo time-lapse images were acquired before
the treatments with a ﬁnal concentration of 100 μg/ml CSE or 100 μg/
ml CSE plus 5mM NAC. Confocal images were acquired in the LSM 510
confocal microscope by using a Plan-Neoﬂuar 100×/1.3 Oil objective,
a 488 nm laser line, and a long-pass (LP) ﬁlter of 560 nm (ﬁlter LP560).
The detector gain, oﬀset, laser potency and pinhole size were main-
tained for all conditions to compare the ﬂuorescence intensity. ImageJ
(http://imagej.nih.gov/) was used to quantify total ﬂuorescence in-
tensity by using corrected total cell ﬂuorescence (CTCF) [26,29,30].
2.11. Mitochondria isolation
Mitochondria were isolated by using diﬀerential centrifugations as
was previously described [13,17,31]. Brieﬂy, cells were seeded at a
density of 25,000 cells/cm2 (p100 dishes have 60 cm2) and cultured for
24 h in 5ml DMEM- 10% FBS, at 37 °C in a humidiﬁed air atmosphere
containing 5% CO2. Then, cells were washed with PBS, scrapped and
centrifuged at 600×g for 5min at 4 °C. The pellet was resuspended in
isolation buﬀer (0.25M sucrose, 25mM MOPS, pH 7.4) and the cells
were permeabilized by adding 0.12% w/v digitonin for 30 s on ice. The
samples were diluted in three volumes of isolation buﬀer and cen-
trifuged at 10,000×g for 20min at 4 °C. The resultant pellet was re-
suspended in 500 µl of isolation buﬀer and centrifuged at 800×g for
10min at 4 °C. The supernatant was centrifuged at 10,000×g for
20min at 4 °C, and the mitochondrial pellet was resuspended in
10–20 µl of BN-sample buﬀer A (1M aminocaproic acid, 50mM bis-
Tris-HCl, 10 μM pepstatin, 10 μM leupeptin, 100 μM PMSF, 1mM
EDTA, pH 7.0) [13,17]. Mitochondrial protein concentration was
measured by Lowry [32] by using aliquots of mitochondrial extract
incubated with 0.1 N NaOH for 30min at 37 °C, to dissolve mitochon-
drial membranes.
2.12. Spectrophotometric determination of mitochondrial NADH-
cytochrome c reductase (mCx-I-III) activity
The NADH-cytochrome c reductase activity (mCx-I plus mCx-III)
was spectrophotometrically measured in mitochondria from Calu-3
cells treated with 100 μg/ml CSE, 100 μg/ml CSE plus 5mM NAC or
vehicle for 24 h, in the presence/absence of rotenone (10 µM), as it was
previously described [13,33,34]. Brieﬂy, mitochondrial preparations
were subjected to three freeze-thaw cycles to make them permeable to
substrates. To measure the mCx-I-III activity, the mitochondria
(equivalent to 100 µg of proteins) were resuspended in buﬀer solution
(100mM H2KPO4/HK2PO4, 0.5mM KCN, 200 μM NADH, 25 μM oxi-
dized cytochrome c, at pH 7.4). The reduction of cytochrome c was
recorded by monitoring the increase in absorbance per minute for 2min
at 550 nm and 30 °C, and expressed as percentage, considering the ac-
tivity in control cells as 100%. To determine the mCx-I activity, in-
hibition of NADH cytochrome c reductase activity by rotenone (10 µM)
was measured in each sample after 5min of preincubation with the
inhibitor and the remaining values (insensitive to rotenone) were sub-
tracted from the total activity.
2.13. Statistics
Unless otherwise indicated, all the assays were performed in du-
plicates and the experiments were repeated at least three times (n=3).
RT-qPCR reactions were carried out by using intra-assay triplicates. The
ﬁnal RT-qPCR quantiﬁcation values were obtained as the means of the
relative quantiﬁcation (RQ) values for each independent experiment
(n= 3). One-way ANOVA and Tukey's post-hoc test was applied to de-
termine signiﬁcant diﬀerences among samples (p < 0.05). All values
are shown as mean ± SEM; the n value (number of replicates) is in-
dicated in each case.
3. Results
3.1. Eﬀects of CSE on Calu-3 cells viability
First, we measured the eﬀects of continuous exposure to several
concentrations of CSE on Calu-3 cells viability. As shown in Fig. 1A,
plotting survival (%) vs CSE concentration (µg/ml), cell viability was
signiﬁcantly diminished only after 72 h of exposure to 100 or 200 µg/
ml (p < 0.001). Similarly, plotting survival (%) vs time (Fig. 1B), a
signiﬁcant inhibition was observed with 100 and 200 µg/ml CSE
(~27% and ~35% respectively) after 72 h of exposure (p < 0.001). In
view of these results, we decided to run further experiments with the
sublethal concentration of 100 µg/ml CSE during 24 h. Treatments for
24 h with NAC (5mM), or CSE (100 µg/ml) + NAC (5mM), did not
have eﬀects on cell viability (Supplementary Fig. 1).
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3.2. CSE aﬀects CFTR expression and activity
Low CFTR levels have been recently associated with COPD [1,10];
therefore, we wanted to validate the use of Calu-3 cells as a model for
COPD measuring CFTR mRNA expression and activity after CSE ex-
posure. As shown in Fig. 2A, the CFTR mRNA in cells exposed to
100 μg/ml of CSE for 24 h was reduced (p < 0.001, n=4) compared
to control cells (vehicle). On the other hand, NAC had not eﬀects on the
CFTR mRNA levels decreased by CSE treatment (Fig. 2A).
Then, to test if the decreased CFTR mRNA expression caused by CSE
was reﬂected in an impairment of the CFTR function, the activity of the
channel was measured by using the chloride sensitive ﬂuorescent probe
SPQ. As shown in Fig. 2B, the CSE treatment decreased both the basal
and the cAMP-stimulated chloride eﬄux. The halide eﬄux slopes, that
reﬂects the activation state of the channel, also showed a lower CFTR
activation in Calu-3 cells treated with CSE (slope = 0.012 ± 0.001;
n=3) compared to control cells (DMSO treated cells) (slope =
0.030 ± 0.001; n= 3). In Fig. 2C, the halide eﬄux slopes were ex-
pressed as percentage referred to control cells as 100%. Thus, cells
treated with CSE showed a signiﬁcant (p < 0.05) decrease, near to
60%, in the activity of the CFTR compared to control cells.
3.3. Eﬀect of CSE on proinﬂammatory cytokines IL-6 and IL-8
To test if the cigarette smoke extract (CSE) induces a proin-
ﬂammatory response in Calu-3 cells, the IL-6 and IL-8 secretion were
Fig. 1. Cell viability in Calu-3 cells exposed to CSE. A: Dose-response cell viability for
CSE exposure (0, 10, 50, 100, and 200 µg/ml) at diﬀerent times (5 dash line, 24 solid line,
48 dot line and 72 dash dot line h). B: Survival vs time plot for CSE exposure at diﬀerent
CSE concentrations (0 dash line, 10 dot line, 50 dash dot line, 100 solid line, and 200 dash
dot dot line µg/ml). Viability was expressed as survival percentage (%) referred to control
cells without CSE treatment (vehicle) as 100%. ** indicates p < 0.01 and *** p < 0.001
compared to control (untreated) cells (n=4). Statistical analyses were performed by
ANOVA and Tukey's test.
Fig. 2. CSE inhibit CFTR mRNA expression and activity. A: CFTRmRNA levels in Calu-
3 cells treated with 100 μg/ml CSE (Cigarette Smoke Extract) or DMSO (vehicle) for 24 h,
measured by quantitative real-time RT-PCR (qRT-PCR). The results were expressed as
arbitrary units (A.U.). Measurements correspond to four independent experiments
(n= 4), each done in duplicate. B: CFTR channel halide transport activity was measured
in Calu-3 cells treated with 100 μg/ml CSE or DMSO by using the SPQ Cl- sensitive probe.
Arrows indicate the times of buﬀers addition; I: NaI buﬀer, II: NaNO3 buﬀer, III: NaNO3
buﬀer + cAMP cocktail, IV: KSCN 150mM + 5 μM valinomycin. Fluorescence values
were calculated as F= (F-Fq)/(Fi-Fq) −1; Fi, are the initial ﬂuorescence values in NaI
buﬀer. Fq corresponds to background values (ﬂuorescence quenching in the presence of
KSCN+valinomycin). The graph is the mean of four independent experiments (n=4). C:
Halide eﬄux slopes, corresponding to SPQ ﬂuorescence changes of Calu-3 cells incubated
with CSE or DMSO. The slopes were calculated from the linear regressions of the ﬁrst 6
points after CFTR stimulation and were plotted as percentage (%) relative to controls. All
data were expressed as mean± SEM. * * indicates p < 0.01 and * p < 0.05, as com-
pared to control cells. Statistical analyses were performed by ANOVA and Tukey's test.
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measured on the cultured media after 24 h incubation. We also tested if
the treatment with the commonly used antioxidant NAC could protect
Calu-3 cells against the CSE oxidative response as occurs in other model
systems [19,23].
As shown in Figs. 3A and 3B, a signiﬁcant (p < 0.01) increase in
the IL-6 (3 A) and IL-8 (3B) secretion was observed in cells treated with
CSE (100 µg/ml, 24 h) compared to control cells (vehicle treated cells).
Noteworthy, the NAC treatment completely reverted the CSE eﬀects,
showing the treated cells similar levels of IL-6 and IL-8 to those ob-
served in control cells. These data suggest that cytokine induction by
CSE was caused by increased cellular ROS levels.
It is known that the expression of proinﬂammatory cytokines is
regulated by the transcription factor NF-κB [35–37], and that its acti-
vation can be induced by increased ROS levels [38–42]. To test if the
increased IL-6 and IL-8 secretion caused by CSE through ROS was
mediated by the NF-κB, Calu-3 cells were incubated with CSE in pre-
sence of 10 µM of the NF-κB pathway inhibitor IKK-2. Co-treatment of
CSE and IKK2 decreased IL-6 and IL-8 secretion compared to Calu-3
cells treated with CSE alone (Figs. 3A and 3B), suggesting that NF-κB is
also involved in the activation by CSE of both cytokines, IL-6 and IL-8.
3.4. CSE increased cellular ROS
Cellular ROS (cROS) levels were measured in cells exposed to CSE
by using the ﬂuorescent probe DCFH-DA. As shown in Fig. 4A, the
ﬂuorescence observed by confocal microscopy in cells exposed to CSE
increased and was highly diﬀused throughout the cells. On the other
hand, NAC (5mM) completely blocked the CSE-induced cROS. Some
remaining ﬂuorescence was observed in NAC treated cells, indicated by
arrows in Fig. 4A. To quantify these responses, the DCF ﬂuorescence
was measured by using a microplate reader. In agreement with the
confocal images, the ROS levels were signiﬁcantly increased in cells
treated with CSE for 1 h compared to control cells (p < 0.05) (Fig. 4B).
In addition, the presence of NAC 5mM reduces the CSE-induced cROS
(Fig. 4B). These results are in agreement with the response of IL-6 and
IL-8 to CSE and NAC (Fig. 3).
3.5. CSE increased mitochondrial ROS
To study the eﬀects of CSE over mitochondrial ROS levels, we used
the mtROS probe MitoSOX and performed a live time-series analysis in
the presence of vehicle, CSE (100 μg/ml) or CSE (100 μg/ml) CSE plus
NAC (5mM). As shown in Fig. 5A (photograph) and 5B (quantiﬁcation
of images ﬂuorescence), it was observed a fast increase (within 5min)
in the mtROS production in cells exposed to CSE. The MitoSOX ﬂuor-
escence intensity in cells treated with CSE plus NAC showed a partial
attenuation by NAC after 5min, which was not longer signiﬁcant after
10min (Fig. 5B). This reduction could be due in part to the presence of
some MitoSOX in cytoplasm (since a high concentration of 5 µM Mi-
toSOX was used) [43]. However, most of the signal is not reduced by
NAC and this is more evident after 10min. The lack of NAC eﬀective-
ness to reduce the CSE-induced mtROS suggests that NAC cannot reach
mitochondria at levels enough to reduce mtROS.
High mtROS levels impair the correct functioning of the mi-
tochondrial proteins and cause mtDNA damage by oxidation
[15,44,45]. Thus, the impairment of the oxidative phosphorylation
system (OXPHOS) by oxidation of some major components, such as the
mitochondrial Complex I and III, might cause a vicious circle of ROS
production that could extend the oxidative damage [15,46]. To test if
CSE exposure caused an impairment in the OXPHOS, the NADH-cyto-
chrome c reductase (mCx-I-III) activity was measured. Mitochondria
were isolated from Calu-3 cells incubated in the presence of vehicle,
100 μg/ml CSE or 100 μg/ml CSE plus 5mM NAC for 24 h. As shown in
Fig. 5C, the mCx-I-III activity decreased (p < 0.05, n=3) in cells ex-
posed to CSE as compared to control cells. Interestingly, NAC treatment
was not able to block the eﬀect of CSE on the mCx-I-III activity
(Fig. 5C).
4. Discussion
The aim of this work was study the eﬀects of NAC treatment over
the proinﬂammatory response produced by CSE in the epithelial airway
cells Calu-3, used as a simpliﬁed in vitro model for COPD [25]. The
results obtained are summarized in Fig. 6, together with the possible
mechanisms involved. Using a CSE concentration and incubation time
of 100 µg/ml during 24 h, no signiﬁcant eﬀects over cells survival were
observed, and this concentration and time were used in subsequent
experiments. CFTR mRNA expression and activity were signiﬁcantly
reduced after CSE exposure, in agreement with previous results from
other laboratories in diverse model systems, showing deleterious eﬀects
of CSE on CFTR activity [1,6–12,47]. Thus, these results suggest that
Calu-3 cells are a good model system for COPD studies.
Using this model system, we observed increased IL-6 and IL-8 levels
Fig. 3. CSE induces IL-8 and IL-6 secretion through NF-κB activation. The eﬀect of
CSE on the proinﬂammatory cytokines IL-8 and IL-6 secretion was evaluated by ELISA in
Calu-3 cells incubated with 100 μg/ml CSE (CSE) for 24 h. The role of the increased ROS
production in the IL-6/IL-8 secretion was tested by incubating with 100 μg/ml CSE
+5mM NAC (CSE+NAC). Calu-3 cells were incubated in presence of 100 μg/ml CSE and
10 µM IKK-2 inhibitor (CSE+IKK-2 inh) to block the NF-κB signal. A) IL-8 and IL-6 (B)
secretion were plotted as percentage compared to control cells as 100% and expressed as
mean ± SEM. * p < 0.05. Statistical analyses were performed by ANOVA and Tukey's
test.
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after CSE exposure. Interestingly, this response was totally reverted by
treatment with NAC, suggesting that a ROS signaling, induced by CSE,
is involved in the production of these proinﬂammatory cytokines. This
is in agreement with prior publications in other model systems
[19,48–51]. It is important to highlight that the increased cytokine
levels were induced directly by CSE, in absence of bacterial infection
(aseptic or sterile inﬂammation) or LPS stimulation, as it has been
proposed by other authors [19,48]. Zhou et al. [51] identiﬁed diﬀerent
CSE compounds that could induce the production of IL-8 in human
epithelium bronchial 16HBE cells, suggesting that the chemical com-
position of the CSE could start the inﬂammatory phenotype in COPD,
previously to any bacterial infection. Also, Ko et al. observed that CSE
exposure induces IL-8 release from macrophages mediated by ROS ac-
tivation of NF-κB through the AMP-activated protein kinase (AMPK).
NAC treatment also attenuated the IL-8 induction [49].
Measuring the DCF ﬂuorescence, a signiﬁcant increase in ROS
Fig. 4. Cellular ROS increase by CSE exposure and NAC protection. A) Confocal image of total cellular ROS levels measured by using DCFH-DA, in cells treated with CSE or CSE+NAC
for 1 h. Images were acquired by using a Plan-Neoﬂuar 100× /1.3 Oil objective, a laser line of 488 nm, and a LP ﬁlter of 505 nm. VIS indicates the visible (transmitted light) image of
cells. Magniﬁcations corresponded to the white squares indicated in the ﬁgures. Arrows indicates regions of intracellular accumulation of ROS. B: Spectroﬂuorometry of cellular ROS
levels measured by using DCFH-DA in cells incubated with 100 μg/ml CSE (CSE), DMSO or 100 μg/ml CSE + 5mM NAC (CSE+NAC) for 1 h.
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production was observed in Calu-3 cells treated with CSE (100 µg/ml)
for 1 h. Interestingly, NAC (5mM) was able to completely block this
eﬀect, as occurred with the IL-6 and IL-8 secretion. On the other hand,
the mitochondrial ROS (mtROS) production, measured by using
MitoSOX, also increased very rapidly after the CSE treatment (in less
than 5min). The NAC treatment produced a partial attenuation in the
MitoSOX signal, signiﬁcant at 5min, which could be in part due to some
MitoSOX accumulated in the cytoplasm [43]. However, the NAC
treatment was insuﬃcient to completely block the induced mtROS at
5min and after 10min the diﬀerences were no longer signiﬁcant.
In addition to the increased mtROS production, after 24 h of ex-
posure to 100 µg/ml CSE, it was observed a decreased mCx-I-III activity
that was not reverted by NAC exposure. These data suggest that this
antioxidant treatment was not eﬀective to block and protect key com-
ponents of the mitochondrial OXPHOS (or that NAC by itself aﬀects the
mCx-I-III activity). Several reports suggest that the inhibition of mCx-I
cause increased ROS levels in some diseases [52,53]. In fact, it has been
previously observed a reduced mCx-I activity and increased ROS pro-
duction in cells with impaired CFTR activity [13–15,27,54]. The fast
mtROS induction observed with CSE (< 5min) suggests that the re-
duction in the CFTR activity and expression, as well as the reduction in
the mCx-I-III activity, occur after the increase in ROS levels. However,
the speciﬁc role of CFTR regarding the inﬂammatory response induced
by CSE is not clear yet, since NAC could not revert the low CFTR levels
induced by CSE, although it normalized the IL-6 and IL-8 levels. Thus,
the reduced CFTR levels could be just a consequence of the CSE treat-
ment, and not the cause for the increased IL-6 and IL-8 levels. Since the
CFTR failure increases IL-1β levels and decreases mCx-I-III activity
[13,55], CFTR might have some role in the CSE-induced proin-
ﬂammatory state and mitochondrial failure, that is not corrected by
NAC treatment. In fact, NAC treatment also failed to normalize the
CFTR levels. A CFTR correction, normalizing the mCx-I-III and ROS
activities, might therefore be of clinical relevance for COPD treatment
[56,57], perhaps accompanied by NAC treatment. However, further
research is needed to better understand the complex mechanisms in-
volved in the CFTR down-regulation and signaling [27,55,58–65], and
particularly under CSE exposure.
We conclude that Calu-3 cells constitute an appropriate in vitro
model to study the eﬀects of CSE on oxidative and proinﬂammatory
responses. A very rapid oxidative stress is developed under CSE ex-
posure, which initiates a sterile proinﬂammatory response, aﬀecting
also the mitochondrial function, the CFTR levels, and causing changes
in ROS production (illustrated in Fig. 6). NAC treatment could inhibit
the CSE cytoplasmic eﬀects on ROS and cytokines, although the mi-
tochondrial eﬀects on ROS were only partially reverted and NAC had no
eﬀects on the reduced mCx-I-III activity. Other inhibitors able to
Fig. 5. Eﬀects of CSE on mitochondrial ROS levels and Complex I-III activity. A) Confocal microscopy corresponding to mitochondrial ROS (mtROS) levels measured by using
MitoSOX at diﬀerent times (0, 1, 5 and 10min) in the presence of 100 µg/ml of CSE. Images were taken by using the time series conﬁguration of the LSM 510 confocal microscope, a Plan-
Neoﬂuar 100×/1.3 Oil objective, a laser ﬁlter of 488 nm, and a LP ﬁlter of 560 nm. VIS indicates the visible image of cells. B) Normalized MitoSOX ﬂuoresce values of corrected total cell
ﬂuorescence (CTCF) corresponding to the images shown in A. Fluorescence was normalized relative to control cells. C: Mitochondrial NADH-cytochrome c reductase (mCx-I-III) measured
in Calu-3 cells incubated with 100 μg/ml CSE (CSE), DMSO or 100 μg/ml CSE + 5mM NAC (CSE+NAC) for 24 h. Data were expressed as mean ± SEM of three independent experiments
(n=3). * indicates p < 0.05 compared to CSE-treated cells. Statistical analyses were performed by ANOVA and Tukey's test.
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circumvent the mitochondrial failure and the low CFTR levels could be
useful to avoid exacerbations in COPD.
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